A phase III study to evaluate WT1 cancer vaccine for the treatment of patients with acute myeloid leukemia

Trial Profile

A phase III study to evaluate WT1 cancer vaccine for the treatment of patients with acute myeloid leukemia

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2016

At a glance

  • Drugs Galinpepimut S (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 03 Oct 2016 According to a Sellas Life Sciences media release, the company expects to initiate this trial in the first half of 2017.
    • 14 Sep 2016 According to Sellas Life Sciences Group media release, this trial is expected to start in early 2017.
    • 14 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Jan 2017, as per Sellas Life Sciences Group media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top